Recent Research Analysts’ Ratings Updates for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (NASDAQ: JAZZ) recently received a number of ratings updates from brokerages and research firms:

• 3/10/2025 – Jazz Pharmaceuticals had its price target raised by analysts at HC Wainwright from $200.00 to $217.00. They now have a “buy” rating on the stock.
• 3/7/2025 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $183.00 price target on the stock, up previously from $175.00.
• 3/7/2025 – Jazz Pharmaceuticals was upgraded by analysts at UBS Group AG from a “neutral” rating to a “buy” rating. They now have a $179.00 price target on the stock, up previously from $145.00.
• 3/6/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Truist Financial Co. from $220.00 to $230.00. They now have a “buy” rating on the stock.
• 3/5/2025 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $210.00 price target on the stock.
• 2/27/2025 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $200.00 price target on the stock, up previously from $190.00.
• 2/26/2025 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $176.00 price target on the stock, up previously from $163.00.
• 2/26/2025 – Jazz Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $200.00 to $209.00. They now have an “overweight” rating on the stock.
• 2/26/2025 – Jazz Pharmaceuticals had its price target lowered by analysts at Royal Bank of Canada from $179.00 to $178.00. They now have an “outperform” rating on the stock.
• 2/26/2025 – Jazz Pharmaceuticals was downgraded by analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating. They now have a $150.00 price target on the stock, up previously from $140.00.
• 2/26/2025 – Jazz Pharmaceuticals had its price target raised by analysts at Needham & Company LLC from $205.00 to $210.00. They now have a “buy” rating on the stock.
• 2/13/2025 – Jazz Pharmaceuticals was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $170.00 price target on the stock, up previously from $130.00.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $137.96 on Monday. The stock has a market capitalization of $8.38 billion, a price-to-earnings ratio of 19.43, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The firm has a 50-day simple moving average of $129.52 and a 200-day simple moving average of $120.84. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insiders Place Their Bets

In other news, CMO Robert Iannone sold 7,080 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at $11,368,526.40. This represents a 7.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,022,825 in the last ninety days. 4.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Large investors have recently modified their holdings of the business. Fuller & Thaler Asset Management Inc. raised its holdings in Jazz Pharmaceuticals by 117.4% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock valued at $115,681,000 after buying an additional 507,234 shares during the period. Darwin Global Management Ltd. purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $59,668,000. Dimensional Fund Advisors LP increased its holdings in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after purchasing an additional 320,724 shares during the last quarter. Ameriprise Financial Inc. raised its position in Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after purchasing an additional 315,608 shares during the period. Finally, GMT Capital Corp lifted its stake in Jazz Pharmaceuticals by 140.0% during the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock worth $62,659,000 after purchasing an additional 296,800 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.